Ke­to in a pill? Jim Mel­lon de­buts an­ti-ag­ing joint ven­ture with the Buck ded­i­cat­ed to in­duc­ing ke­to­sis

Jim Mel­lon

Click on the im­age to see the full-sized ver­sion


Jim Mel­lon’s crew at Ju­ve­nes­cence has found its lat­est ven­ture idea in a pop­u­lar di­et mak­ing its rounds in biotech cir­cles.

Er­ic Verdin

Once again team­ing up with the Buck In­sti­tute for Re­search on Ag­ing, Ju­ve­nes­cence has launched BHB Ther­a­peu­tics to ex­plore pre­ven­ta­tive med­i­cines that have po­ten­tial to pro­tect against age-re­lat­ed dis­ease by in­duc­ing a state of ke­to­sis, where the body burns fat in­stead of carbs, spurring the pro­duc­tion of an­ti-in­flam­ma­to­ry ke­tone bod­ies.

In par­tic­u­lar, the biotech start­up will fo­cus on the ke­tone body be­ta-hy­drox­y­bu­tyrate, or — you guessed it — BHB. Er­ic Verdin, the Buck pres­i­dent and CEO whose re­search in­spired an­oth­er Ju­ve­nes­cence spin­out, has dis­cov­ered that BHB helps the body re­spond to stress.

John New­man

A ke­to­genic di­et — which has been her­ald­ed for its ef­fects in weight loss, hunger sup­pres­sion as well as con­cen­tra­tion — and the con­se­quent longterm ex­po­sure to ke­tone bod­ies can al­so ex­tend healthy lifes­pan in mod­el sys­tems, Verdin and col­lab­o­ra­tor John New­man found.

The duo has gen­er­at­ed “hard sci­en­tif­ic da­ta” in mice that show ke­to­sis can be car­dio-pro­tec­tive, CEO Greg Bai­ley told End­points News. Ob­vi­ous­ly, they have a long way to go.

“The rea­son we think that car­dio-pro­tec­tion may trans­late to hu­mans is be­cause if giv­en sug­ar or ke­tones, many peo­ple’s hearts pre­fer ke­tones, where­as the brain is the op­po­site,” he said. “If giv­en the op­tion be­tween sug­ar or ke­tones, the brain will take sug­ar. Un­for­tu­nate­ly, in­di­vid­u­als when they hit 50 (plus or mi­nus a cou­ple years) they be­come in­sulin re­sis­tant — and then the sug­ar can go se­ri­ous­ly high in a va­ri­ety of or­gans and that leads to a va­ri­ety of dif­fer­ent patholo­gies.”

The com­pa­ny is look­ing to be­gin “ag­gres­sive safe­ty stud­ies” in the near-term, Bai­ley added. Should the com­pounds be found safe, he plans to take al­ter­na­tive routes rather than the con­ven­tion­al reg­u­la­to­ry path­way — which he be­lieves can lead to quick­er hu­man test­ing.

Greg Bai­ley

Just days ago, Ju­ve­nes­cence un­veiled the first $46 mil­lion tranche of a promised $100 mil­lion raise that’s de­signed to bankroll longevi­ty projects with the col­lec­tive goal of ex­tend­ing the hu­man lifes­pan to 150 years. So far, it’s ticked off stem cell tech and or­gan re­gen­er­a­tion among the fields it’s es­tab­lished it­self through joint ven­tures with AI groups — In­sil­i­co and Ne­tra­mark — and con­trol­ling in­ter­ests in AgeX and Ly­Ge­n­e­sis.

The goal, founder and chair­man Mel­lon said back then, is to have 18 projects un­der­way by the end of the year.

Look for two or three of them to be an­nounced over the next few weeks, Bai­ley said, not­ing that there should al­so be three or four let­ters of in­tent go­ing out short­ly.


With ad­di­tion­al re­port­ing by Na­tal­ie Grover.

Bio­mark­er 'roadmap­s' and the fu­ture of can­cer R&D; Cur­tain rais­es on #AS­CO22; Pfiz­er, No­var­tis tack­le drug ac­cess; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

While this was not a week for earth-shattering news, there were certainly a lot of interesting tidbits. If you found this recap helpful, please recommend it to your friends and colleagues. We’ll see you on the other side of the long weekend.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

Keep­ing pres­sure on Am­gen, Mi­rati draws mixed re­views on lat­est cut of KRAS da­ta

As the close runner-up to Amgen’s Lumakras in the KRAS race, any data cut from Mirati’s adagrasib continues to draw scrutiny from analysts. And the latest batch of numbers from ASCO is a decidedly mixed bag.

While a quick comparison suggests that adagrasib spurred slightly more responses and led to a longer overall survival than Lumakras among a group of non-small cell lung cancer patients, its duration of response appears shorter and the safety profile continues to spark concern.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

Ann is one of ViiV Healthcare's newest spokespeople as the retired school administrator speaks up about her HIV status.

GSK's Vi­iV de­buts next evo­lu­tion in HIV med Dova­to cam­paign with new spokes­peo­ple and new mes­sage

When Ann saw the first TV commercials for HIV medicine Dovato, she didn’t see herself represented. So the 74-year-old retired school administrator who’s been living with HIV since 1998, reached out to GSK’s ViiV Healthcare and asked why not?

Now Ann is one of three people starring in ViiV’s latest Dovato campaign called “Detect This.” The next-step evolution in the branded campaign plays on the word “detect” — often used in describing HIV status under control as undetectable — but in this case, uses the word as a directive for people to understand they can use fewer medicines.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

Tran­si­tion to new Eu­ro­pean clin­i­cal tri­als in­fo sys­tem starts slow­ly

At the end of January, the European Medicines Agency officially launched its new clinical trials info system (CTIS), although the migration to the new platform has only really just begun, and sponsors have until the end of January 2023 before all initial trial applications must be submitted through CTIS.

Overall, 56 clinical trial applications have been submitted in CTIS during the first 3 months since the launch of the system on Jan. 31, according to new data posted by the EMA. By comparison, about 4,000 new trials are authorized each year across Europe.

Switzer­land to de­stroy over 600,000 ex­pired dos­es of Mod­er­na Covid vac­cine

As concerns related to uptake and distribution continue to linger, Switzerland is among the first countries that plans to destroy hundreds of thousands of expired and unused Covid-19 vaccine doses.

The European country said it plans to destroy more than 600,000 doses of Moderna’s Spikevax Covid-19 vaccine as the doses have reached their expiration date.

However, Moderna CEO Stéphane Bancel told the World Economic Forum in Davos, Switzerland that he’s in the process of throwing 30 million doses in the garbage, exclaiming, “We have a big demand problem.”

Nassim Usman, Catalyst Biosciences CEO

Af­ter $60M Ver­tex deal, group of Cat­a­lyst share­hold­ers claims biotech could’ve sold as­sets three years ago

Catalyst Biosciences was down to five employees in March, and the biotech needed to do something after two rounds of layoffs, a nixed collaboration and a culling of its hemophilia program.

In came Vertex, with $60 million to buy up the South San Francisco biotech’s preclinical complement drugs, which target the system that bridges the body’s innate and adaptive immune response and a class most known for Ultomiris and Soliris. The deal includes CB 2782-PEG, the dry AMD drug that Biogen no longer wanted in March.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

Lina Khan, FTC chair (Graeme Jennings/Pool via AP Images)

Pile-on over PBMs con­tin­ues with FTC com­ments and a new bi­par­ti­san Sen­ate bill

More than 500 stakeholders sent comments to the FTC on whether the commission should look further into pharma middlemen, known as PBMs, with many of the commenters calling for more federal oversight.

Similar to the critical open comment period in a deadlocked FTC session last February, pharmacies and pharmacy groups are continuing to call out the lack of transparency among the top 3 PBMs, which control about 80% of the market.

Pharma brands are losing their shine with US consumers who are now thinking about the economy and inflation instead of Covid. (Credit: Shutterstock)

Phar­ma brands fade in an­nu­al Har­ris con­sumer vis­i­bil­i­ty poll: Mod­er­na drops off and Pfiz­er dips

As Covid-19 concerns are fading in the US, so is biopharma visibility. The annual Axios Harris Poll survey to determine and rank the 100 most top-of-mind brands in the US finds Moderna, which was No. 3 last year, not on the list at all for 2022, and Pfizer sinking 37 spots.

However, it’s not that Moderna or Pfizer did anything wrong, it’s just that Americans have moved on to other worries beyond Covid.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

HHS Secretary Xavier Becerra (Jacquelyn Martin/AP Images)

HHS fin­ish­es off Trump-era rule that would've erased ba­sic FDA regs with­out fre­quent re­views

HHS on Thursday finalized its decision to withdraw a rule, proposed just before former President Donald Trump left office, that would’ve caused thousands of HHS and FDA regulations to automatically expire if they weren’t reviewed within two years, and every 10 years thereafter.

The decision follows the filing of a lawsuit last March, in which several nonprofits alleged that the outgoing administration planted “a ticking timebomb” for HHS, essentially forcing it to devote an enormous amount of resources to the unprecedented and infeasible task of reviewing thousands of regulations regularly.